Hyponatremia and hypernatremia have an opposing effect on overall survival in neuroendocrine tumor patients treated with peptide receptor radionuclide therapy

#3213

Introduction: Hypo- and hypernatremia are common electrolyte abnormalities in patients with malignancy and have been independently associated with worse survival outcomes. To date, there is no data on the influence of dysnatremia on patients with neuroendocrine tumors (NET).

Aim(s): Survival comparison of NET patients with and without development of dysnatremia.

Materials and methods: Retrospective cohort analysis of patients treated with peptide receptor radionuclide therapy (PRRT). Occurrence of hyponatremia (p-sodium < 135 mmol/l) and hypernatremia (p-sodium > 145 mmol) was assessed at baseline and within the first 4 cycles of PRRT. Patients treated with a cumulative dose of at least 100 mCi (3.7 GBq) 177Lu-DOTATATE were included.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Refardt J, Brabander T, Minczeles N, Feelders R, de Herder W,

Keywords: hyponatremia, hypernatremia, survival, PRRT,